<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789538</url>
  </required_header>
  <id_info>
    <org_study_id>ASPHINA 509 BER-401-20</org_study_id>
    <nct_id>NCT04789538</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of an Hydrophilic Acrylic Intraocular Lens</brief_title>
  <official_title>Retro-prospective Evaluation of the Clinical Safety and Effectiveness of Hydrophilic Acrylic Intraocular Lens (509)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the clinical safety and effectiveness of hydrophilic acrylic intraocular lens&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To show safety and the effectiveness in regard to the monocular corrected distance visual&#xD;
      acuity (CDVA) at 12-24 month postoperative.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 to 24 months after the implantation</time_frame>
    <description>Visual acuity at far distance</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">325</enrollment>
  <condition>Cataract Senile</condition>
  <arm_group>
    <arm_group_label>Monofocal IOL</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>monofocal lens</intervention_name>
    <description>not applicable as patients are already implanted with the monofocal intraocular lens</description>
    <arm_group_label>Monofocal IOL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients implanted with the study lens IOLs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of any gender, aged 18 years or older at the time of the surgery&#xD;
&#xD;
          -  Patients who had an uncomplicated (no intra-operative complication) aged-related&#xD;
             cataract surgery&#xD;
&#xD;
          -  Currently implanted with the study device into the capsular bag in at least one eye&#xD;
&#xD;
          -  One-year post surgery follow-up (365 days -14 days/+365 days) for the study eye at the&#xD;
             time of the postoperative visit&#xD;
&#xD;
          -  Patient is willing and capable of providing informed consent&#xD;
&#xD;
          -  Patient is willing and capable of complying with visits and procedures as defined by&#xD;
             this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preoperative corrected distance visual acuity (CDVA) better than 0.3 LogMAR (0.5&#xD;
             decimal) or CDVA not available preoperatively&#xD;
&#xD;
          -  Preoperative documented endothelial cell count of less than 2000/mm2 (if available)&#xD;
&#xD;
          -  Any preoperative documented ocular disorder that could potentially cause a clinically&#xD;
             significant future visual acuity loss&#xD;
&#xD;
          -  Any preoperative documented clinically significant anterior segment pathology (e.g.&#xD;
             chronic uveitis, iritis, aniridia, rubeosis iridis, anterior membrane dystrophies,&#xD;
             poor pupil dilation, etc.)&#xD;
&#xD;
          -  Any preoperative documented clinically significant abnormal corneal finding (e.g.&#xD;
             keratoconus, pellucid marginal degeneration, or irregular astigmatism, clinically&#xD;
             significant corneal membrane dystrophies)&#xD;
&#xD;
          -  Any preoperative documented clinically significant condition that could affect IOL&#xD;
             stability (e.g. zonular dialysis, evident zonular weakness or dehiscence, etc.)&#xD;
&#xD;
          -  Any preoperative documented history of clinically significant retinal pathologies or&#xD;
             ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration,&#xD;
             retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus,&#xD;
             microphthalmos, aniridia, epiretinal membrane etc.) that could alter or limit final&#xD;
             postoperative visual prognosis&#xD;
&#xD;
          -  Any preoperative acute infection (acute ocular disease, external/internal infection,&#xD;
             systemic infection)&#xD;
&#xD;
          -  Any previous preoperative intraocular and corneal surgery&#xD;
&#xD;
          -  Preoperative documented uncontrolled glaucoma or IOP higher than 24mmHg under ocular&#xD;
             hypertension treatment&#xD;
&#xD;
          -  Preoperative documented or current systemic or ocular pharmacotherapy that effects&#xD;
             patients' vision&#xD;
&#xD;
          -  Any other preoperative documented or current pathology or condition that could be a&#xD;
             risk for the patient according to the investigator opinion&#xD;
&#xD;
          -  Women during pregnancy and/or lactation at time of enrollment into the study&#xD;
&#xD;
          -  Patients unable to meet the limitations of the protocol or likely of non-cooperation&#xD;
             during the trial&#xD;
&#xD;
          -  Patients whose freedom is impaired by administrative or legal order&#xD;
&#xD;
          -  Subject is enrolled in any other concurrent clinical study, with the exception of&#xD;
             local mandatory governmental registries and observational studies/registries, that do&#xD;
             not affect patients' vision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>CZM CA</last_name>
    <phone>0049308540010</phone>
    <email>clinicalstudies.meditec.sur@zeiss.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Desgenettes</name>
      <address>
        <city>Lyon</city>
        <zip>69275</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Corinne Dot, Prof</last_name>
      <phone>04 72 36 61 00</phone>
      <email>corinnedot.pro@hotmail.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

